Klein Joseph III's Form 4 filing
Ionis Pharmaceuticals Inc (IONS) · filed Mar 5, 2026
- Accession no.
- 0000874015-26-000137
- Filed
- Mar 5, 2026
- Trade date
- Mar 3, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.70M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Klein Joseph IIICIK 0001206369 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Common Stock | MOption exerciseAcquired | +12,000 | $40.05 | +$480,600 | 28,346 | Direct | |
| Mar 3, 2026 | Common Stock | MOption exerciseAcquired | +4,000 | $42.88 | +$171,520 | 32,346 | Direct | |
| Mar 3, 2026 | Common Stock | SSaleDisposed | −13,526 | $79.17 | −$1,070,853.42 | 18,820 | Direct | |
| Mar 3, 2026 | Common Stock | SSaleDisposed | −6,794 | $80.00 | −$543,520 | 12,026 | Direct | |
| Mar 3, 2026 | Common Stock | SSaleDisposed | −1,012 | $80.82 | −$81,789.84 | 11,014 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Common Stock | MOption exerciseDisposed | −12,000 | $0.00 | $0 | 0 | Direct | |
| Mar 3, 2026 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.